← Leaderboards
John W Evankovich
University Of Pittsburgh At Pittsburgh
$2,454,887
Attributed
$2,454,887
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $806.2K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,454,887 · 5
By mechanism
K08$809,502 · 1
R01$688,163 · 1
R56$607,952 · 1
R03$236,140 · 1
F32$113,130 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Hulya Bayir$16,376,338
- Adam Carl Straub$12,143,477
- Anthony John Kanai$13,693,260
- Wen Xie$22,052,503
- Joel S Greenberger$22,565,586
Others in their field
Other Emerging Leaders on “Pathway Interactions”
- April Brinkoetter · Hungry Heart Media, Inc.$59,802,265
- Kevin Urdahl · Seattle Children'S Hospital$47,227,116
- Urs Ochsner · Crestone, Inc.$38,569,476
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Nader Fotouhi · Global Alliance For Tb Drug Development$28,468,137
- Jeffrey Glenn · Stanford University$26,017,226
Research focus
Pathway InteractionsResponseInflammatoryMolecularMortalityMedicineCritical CareUniversitiesProgramsPhysiciansSignal TransductionLungPatternPathologicDegradation PathwayMediatingNovel StrategiesProteinsInsightPhenotypeInflammationLigandsLung InjuryAward
Grant awards (11)
Indole Metabolites as Xenobiotic Danger signals in Acute Lung Injury$688,163
R01 · FY2025 · HL · contact PI
Fibronectin Extra Domain A Degradation as an Antifibrotic Approach in Lung Fibrosis$118,070
R03 · FY2025 · HL · contact PI
Indole Metabolites as Xenobiotic Danger signals in Acute Lung Injury$607,952
R56 · FY2024 · HL · contact PI
Fibronectin Extra Domain A Degradation as an Antifibrotic Approach in Lung Fibrosis$118,070
R03 · FY2024 · HL · contact PI
Degradation of Toll-Like Receptor 8 by RNF216 in response to plasma MicroRNAâÂÂs â A Novel Mechanism Regulating Inflammation in Acute Lung Injury$161,242
K08 · FY2023 · HL · contact PI
Degradation of Toll-Like Receptor 8 by RNF216 in response to plasma MicroRNAâÂÂs â A Novel Mechanism Regulating Inflammation in Acute Lung Injury$161,581
K08 · FY2022 · HL · contact PI
Degradation of Toll-Like Receptor 8 by RNF216 in response to plasma MicroRNAâÂÂs â A Novel Mechanism Regulating Inflammation in Acute Lung Injury$161,910
K08 · FY2021 · HL · contact PI
Degradation of Toll-Like Receptor 8 by RNF216 in response to plasma MicroRNAâs â A Novel Mechanism Regulating Inflammation in Acute Lung Injury$162,230
K08 · FY2020 · HL · contact PI
Degradation of Toll-Like Receptor 8 by RNF216 in response to plasma MicroRNAâs â A Novel Mechanism Regulating Inflammation in Acute Lung Injury$162,539
K08 · FY2019 · HL · contact PI
Degradation of The Receptor for Advanced Glycation End Products (RAGE) - A Novel Mechanism in Lung Epithelial Cell Injury$50,052
F32 · FY2018 · HL · contact PI
Degradation of The Receptor for Advanced Glycation End Products (RAGE) - A Novel Mechanism in Lung Epithelial Cell Injury$63,078
F32 · FY2017 · HL · contact PI